Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 9 - Drugs for disorders of the cardiovascular system
Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484)
11/2005
11/03/2005CA2835840A1 Beneficial effects of increasing local blood flow
11/03/2005CA2564066A1 Carotenoid analogs or derivatives for the inhibition and amelioration of inflammation
11/03/2005CA2563874A1 Erythropoietin protein variants
11/03/2005CA2563756A1 Phenyl acetamides
11/03/2005CA2563741A1 Antisense oligonucleotides against cpla2, compositions and uses thereof
11/03/2005CA2561390A1 Methods and compositions for the treatment of myocardial conditions
11/02/2005EP1591443A1 Pyrazole derivative
11/02/2005EP1591437A2 Interleukin-1 and tumor necrosis factor-alpha modulators, syntheses of said modulators and methods of using said modulators
11/02/2005EP1591135A1 Drug/drug delivery systems for the prevention and treatment of vascular disease
11/02/2005EP1591129A2 Use of neurotoxic component of botulinum toxin for treating pain associated with cervical dystonia or bepharospasm
11/02/2005EP1591124A1 Galenic preparation for anal administration in the treatment of haemorrhoids
11/02/2005EP1591120A1 Receptor agonists
11/02/2005EP1591113A1 Blood pressure-lowering agent, vascular flexibility-improving agent and foods having these functions imparted thereto
11/02/2005EP1591108A2 Solution formulations of sirolimus and its analogs for CAD treatment
11/02/2005EP1591020A1 Compositions containing coenzyme q10
11/02/2005EP1590448A1 Method of preparing cell for transplantation
11/02/2005EP1590339A2 Chemical compounds
11/02/2005EP1590321A2 Aryl alkyl carbamate derivatives production and use thereof in therapy
11/02/2005EP1589991A1 Long acting insulin for reducing cardiovascular morbidity and mortality in prediabetic patients and patients with type 2 diabetes
11/02/2005EP1589986A2 Methods and uses of the integrin alpha 10 chain, for preventing progression of atherosclerosis plaque formation
11/02/2005EP1589966A2 Preparation of new pharmaceutically suitable salt of losartan and forms thereof with new purification and isolation methods
11/02/2005EP1589964A1 Compounds having anti-proliferative properties
11/02/2005EP1589963A1 Use of 10-aminoaliphatyl-dibenz b,f oxepines for the tr eatment of degenerative ocular disorders
11/02/2005EP1589815A2 POLYCOSANOLS FROM i ERICERUS PELA /i WAX
11/02/2005EP1507758B1 Indole derivatives and their use as ligands for cb2 receptors
11/02/2005EP1501833B1 N-substituted-heteroaryloxy-aryl-spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors
11/02/2005EP1501525B1 Method for producing preparations rich in tocotrienol
11/02/2005EP1501515B1 Triaryl-oxy-aryloxy-pyrimidine-2,4,6-trione metalloproteinase inhibitors
11/02/2005EP1476164B1 Quinoxalinones and their use especially in the treatment of cardiovascular diseases
11/02/2005EP1427415A4 Lactam-containing compounds and derivatives thereof as factor xa inhibitors
11/02/2005EP1425007B1 Use of c2-substituted indane-1-ol systems for producing medicaments for the prophylaxis or treatment of obesity
11/02/2005EP1377569B1 Substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines with adenosine receptor-binding activity and their use as cardiovascular preparations
11/02/2005EP1357930B1 Histidine-rich glycoprotein (hrgp) for inhibiting angiogenesis
11/02/2005EP1332149B1 Glycerophosphoinositol derivatives as modulators of cytosolic a2 phospholipase
11/02/2005EP1311501B1 Antithrombotic agents
11/02/2005EP1278719B1 Naphthamide neurokinin antagonists for use as medicaments
11/02/2005EP1246807B1 Novel hydantoin, thiohydantoin, pyrimidinedione and thioxopyrimidinone derivatives, preparation method and use as medicines
11/02/2005EP1237902B1 Halogenated sulphamate-, phosphonate-, thiophosphonate-, sulphonate- and sulphonamide- compounds as inhibitors of steroid sulphatase
11/02/2005EP1169244B1 Metering valve
11/02/2005EP1157000B1 Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of diabetic retinopathy
11/02/2005EP1117443B1 Peptide-based carrier devices for stellate cells
11/02/2005EP1102767B1 Substituted pyrazole derivatives
11/02/2005EP1083905B1 Medical use of a selective estrogen receptor modulator in combination with a sex steroide precursor
11/02/2005EP0929520B1 Indolinone combinatorial libraries and related products and methods for the treatment of disease
11/02/2005CN1692123A Compounds, compositions and methods for treatment of inflammatory diseases and conditions
11/02/2005CN1692116A Adenosine A2A receptor antagonists
11/02/2005CN1692115A Pyrrolopyrimidine and pyrrolopyridine derivatives substituted with cyclic amino group
11/02/2005CN1691959A Interleukin 6 production inhibitor
11/02/2005CN1691958A Enos mutants useful for gene therapy
11/02/2005CN1691957A 蛋白酶抑制剂 Protease inhibitors
11/02/2005CN1691945A Use of rapamycin for inhibiting of cell death
11/02/2005CN1690057A Selenophen derivatives and their use for prevention and/or treatment of diseases relative to protein aging
11/02/2005CN1689563A Application of butylbenzene phthalein homolog in preparation of medicine for treating cerebral ischemia disease
11/02/2005CN1225557C Method for producing blood vessel diseases gene medicine-blood vessel endothelium growth gene-2 naked DNA by microorganism cloning vehicle
11/02/2005CN1225466C Sodium-hydrogen exchanger type 1 inhibitor (NHE-1)
11/02/2005CN1225463C Arylated furane and thenoyl amine with potassium channel blocking effect
11/02/2005CN1225276C Preparation method of red peony root injection
11/02/2005CN1225272C Chinese medicine for treating piles
11/02/2005CN1225270C Medicine for treating atherosclerosis and its preparing method
11/02/2005CN1225264C Heart strengthening tablets and preparation thereof
11/02/2005CN1225259C Chinese medicinal composition for treating cerebral arteriosclersis and the preparation process thereof
11/02/2005CN1225244C Composite blood pressure reducing preparation containing indapamide and beta retarder or beta and alpha retarder
11/01/2005US6960688 Use of compounds for the elevation of pyruvate dehydrogenase activity
11/01/2005US6960683 Antiinflammatory agents; autoimmune diseases; cardiovascular disorders
11/01/2005US6960674 A lipoxin compound for treating polymorphoneutrophil (PMN) inflammation
11/01/2005US6960661 [7-(3-chloro-4-methoxybenzlamino)-1-methyl-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-ylmethoxy]acetic acid, synthesis thereof and intermediates used therein
11/01/2005US6960648 Peptide transporters that specifically target certain cell types for the delivery of drugs and therapeutic agents
11/01/2005US6960614 Oxygenated esters of 4-lodo phenylamino benzhydroxamic acids
11/01/2005US6960609 Analgesics; central nervous system disorders; gastrointestinal disorder; therapy for drug abruse ; antiinflammatory agents
11/01/2005US6960605 Thiazole, imidazole and oxazole compounds and treatments of disorders associated with protein aging
11/01/2005US6960602 Piperidine derivatives as modulators of chemokine receptors
11/01/2005US6960601 Imidazole derivatives; appetite suppressants
11/01/2005US6960599 Dopamine D2 receptor and 5-HT1A antagonists; schizophrenia; cognitive activators; Alzheimer's disease; brain disorders; strokes; antiischemic agents; anxiolytic agents; obsessive compulsive disorder; eating, sleeping and sexual disorders
11/01/2005US6960597 Aza-bridged-bicyclic amino acid derivatives as α4 integrin antagonists
11/01/2005US6960590 Orally active salts with tyrosine kinase activity
11/01/2005US6960587 Piperido(1,2-a)piperazine-1,4-dione derivatives fused to a 5-7 membered ring at the 7-8 position; cGMP-specific PDE inhibitors; treatment of cardiovascular disorders and erectile dysfunction.
11/01/2005US6960583 Pyrazolotriazines as CRF antagonists
11/01/2005US6960581 1-amino-2-hydroxy-butane or 2-hydroxy-butanamide derivatives
11/01/2005US6960578 Glutamate receptor antagonists
11/01/2005US6960575 Thiazine derivatives
11/01/2005US6960444 Transcriptional mediators of blood vessel development and endothelial differentiation
11/01/2005CA2383351C Xanthine derivatives as selective antagonists of a2b adenosine receptors
10/2005
10/27/2005WO2005100987A1 Novel ligand of g protein coupled receptor protein and use thereof
10/27/2005WO2005100570A1 Earthworm fribrinolytic enzyme gene, genetic engineering strains, and the construction and usages thereof
10/27/2005WO2005100562A1 OSTEOPONTIN siRNA
10/27/2005WO2005100558A1 Cd40 ligand mutant and utilization of the same
10/27/2005WO2005100349A2 Polycyclic pyridines as potassium ion channel modulators
10/27/2005WO2005100325A1 Aryl glycinamide derivatives and their use as nk1 antagonists and serotonin reuptake inhibithors
10/27/2005WO2005100324A1 2- ( arylalkoxy ) -1- phenylethylamine derivatives as nk1 antagonist and serotonin reuptake inhibitors
10/27/2005WO2005099760A1 Solid pharmaceutical preparation
10/27/2005WO2005099759A1 Medicine for prevention and/or treatment of arteriosclerosis
10/27/2005WO2005099696A1 Medicine comprising combination of acetylcholine esterase inhibitor and 5-substituted 3-oxadiazolyl-1,6-naphthyridin-2(1h)-one derivative
10/27/2005WO2005099682A1 Preparations for external use
10/27/2005WO2005099681A1 Tablet containing branched chain amino acid and process for producing the same
10/27/2005WO2004089903A9 Piperidine derivatives as renin inhibitors for the treatment of hypertension
10/27/2005WO2003023008A8 Therapeutic polypeptides, nucleic acids encoding same, and methods of use
10/27/2005US20050240027 Carvedilol phosphate salts and/or solvates thereof, corresponding compositions and/or methods of treatment
10/27/2005US20050240017 5-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-5,11-dihydro-6-oxa-12-thia-dibenzo[a,f]azulen-2-ol; 13-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-7,13-dihydro-12-oxa-benzo[4,5]cyclohepta[1,2-a]naphthalen-3-ol or derivatives or salts; for alleviating symptoms of estrogen deprivation, including bone loss
10/27/2005US20050239896 A 5-(2,3,5,6-tetrafluoro-4-trifluoromethyl-benzylamino)-benzoic acid, acid ester, sulfonic acid or amide derivatives, for treating Alzheimer's disease, Parkinson's disease and Huntington's disease, epilepsy, stroke, depression, glaucoma
10/27/2005US20050239884 Compositions comprising hmg-coa reductase inhibitor
1 ... 744 745 746 747 748 749 750 751 752 753 754 755 756 757 758 759 760 761 762 763 764 ... 1595